(a) Two-dimension Z score plot of TNF and IL-1β production by THP-1 cells upon target gene knockdown using a selected group of constructs of the TRC shRNA lentiviral vector library followed by PFA-fixed E. coli stimulation for 24 hours. Each dot represents an individual construct. Dotted horizontal and vertical lines define the area in which genes are considered primary hits. Black dots identify ATM (1), ATR (2) and CHECK1 (3). (b) Epirubicin activates ATM as shown by Flow cytometry analysis of the activated form of ATM, phosphorilated at serine 1981, in THP-1 cells left untreated (C) or treated with epirubicin alone (1µM) (5 hours) (Epi), challenged with PFA-fixed E. coli (4 hours) (E. coli) or E. coli (4 hours) plus epirubicin pre-treatment (1 hour) (E. coli + Epi), and (c) Immunoblotting of total protein extracts of THP-1 cells untreated or pre-treated with epirubicin (1mM) and challenged with PFA-fixed E. coli at indicated timepoints probed for the total and phosphorylated (serine 1981) forms of ATM. Tables   ID  MOLECULE NAME  Z Supplemental Table S2 -shRNA-based identification of negative regulators of IL-1β secretion in response to E. coli, in THP-1 cells. Related to Figure 3 .
Supplemental Experimental Procedures

Figure S1
Chemical Screen THP-1 human monocytes were plated in 96-well plates at 10 6 cell/ml and incubated with each of the ~2320 compounds included in the Spectrum collection (Microsource Discovery Systems, Gaylordsville, CT) at 10 M for 1 hour. Cells were challenged with 4% PFA-fixed DH5a E.coli at a Multiplicity of Infection (MOI) of 20 bacterial cells per THP-1 cell for an additional 24 hours. The cell supernatants were collected and IL-1β and TNF cytokines quantified by DAS-ELISA, using Human IL-1β /IL-1F2 DuoSet® and Human TNF DuoSet® (R&D Systems®), respectively.
Figure S3
While epirubicin decreased both IL-1β and TNF secretion in THP-1 cells, only IL-1β, but not TNF, was up-regulated after ATM or ATR silencing (Supplemental Table S2 and S3). Similar results were obtained in THP-1 cells using the ATM specific pharmacologic inhibitor KU-55933 ( Figure S3d) . Similarly, treatment of bone marrow-derived macrophages with epirubicin inhibited IL-1β and TNF secretion ( Figure S3e ). However, this inhibition was also observed in ATM-deficient bone marrow derived macrophages, suggesting that epirubicin can inhibit IL-1β secretion via a mechanism that is not strictly ATM dependent ( Figure S3f ).
The RNAi Consortium Library
Detailed description of the RNAi Consortium (TRC) lentiviral RNAi library used in this study was originally described in (Moffat et al., 2006) . More details can be found at www.broad.mit.edu/rnai/trc/lib.
shRNA-based Screen
We generated a working subset of The RNAi Consortium (TRC) shRNA lentiviral vector library (Moffat et al., 2006) that allows for the silencing of most of the genes that are either human kinases or phosphatases. This subset was composed of 1440 individually arrayed lentiviral shRNA vectors targeting ~700 genes, after selecting the most efficient shRNAs (two on average) based on available silencing efficiency data from the Broad Institute of MIT and Harvard. THP-1 cells were plated in 96-well plates at 10 6 cell/ml and infected with shRNA-expressing lentivirus. 48 hrs later infected cells were selected with puromycin. After the 3 days of selection, plates were duplicated. One of the plates was used to measure the cell number using Alamar Blue® cell viability assay (Invitrogen®). In the other plate, cells were stimulated with 4% PFA-fixed DH5a E.coli at a Multiplicity of Infection (MOI) of 20 bacterial cells per THP-1 cell. Twenty-four hours after stimulation, cell supernatants were collected and IL-1β and TNF cytokines quantified by DAS-ELISA. All data values from IL-1β and TNF secretion assays were normalized by dividing the amount of IL-1β and TNF in the conditioned media 24, 12, 8, 6, 4 or 2 hrs after E. coli stimulation by the number of cells in each well and then by the average concentration per cell of the plate. Results were logarithmic natural transformed. Scores were sorted in ascending order and graphed. We calculated 1.5 SDEVs above and below the mean to identify the genes that changed IL-1β and TNF secretion when silenced. The same approach was used to identify the compounds that changed IL-1β and TNF secretion. The selected genes were submitted to two or more rounds of phenotypic validation.
Figure S4
We explored several additional possible ATM-dependent mechanisms to explain the protective role of epirubicin in sepsis. We found that, in vitro, epirubicin is able to counteract the increase in ROS generated by E. coli challenge of THP-1 cells in an ATM dependent manner ( Figure S4a) . However, mice that are deficient for the nuclear factor (erythroid-derived 2)-like 2 (NRF2), a master regulator of ROS scavenging (Lee et al., 2005) , are still protected by epirubicin against mortality due to CLP ( Figure S4b ). Therefore, epirubicin induces an ATM-dependent ROS scavenging response that is largely dispensable for its protective effect in sepsis. Increased apoptosis of neutrophils can attenuate sepsis pathogenesis (Garrison et al., 2011) . This would be a simple and attractive hypothesis considering that anthracyclines initiate a DDR leading to increased apoptosis if the DNA lesion is too severe for repair (Garrison et al., 2011) . However, our data shows that epirubicin treated mice have higher, not lower, numbers of viable neutrophils in the abdomen, excluding an important role for this mechanism ( Figure S4c ).
The biogenesis of some miRNAs, including miR-146a (a negative regulator of inflammation (Taganov et al., 2007) and a proposed biomarker in sepsis (Wang et al., 2010) ), is ATM-dependent (Zhang et al., 2011) . We compared the survival of wild-type mice with that of miR-146a -deficient mice in the presence or absence of epirubicin. We conclude that the protection given by this drug is dependent on the presence of miR-146a ( Figure S4e ). However, our RT-qPCR analysis of miR-146a expression in either RAW cells or THP-1 cells ( Figure S4f ) does not support a role for epirubicin in the induction of this microRNA. Therefore, direct induction of miR-146a is not the mechanism by which epirubicin protects against the LPS model of septic shock or CLP.
